

Listing of Claims:

1. (Currently Amended) A transgenic nonhuman mammal whose germ ~~or~~ and somatic cells contain (i) a first heterologous nucleic acid sequence encoding a transcriptional activator whose expression is under the control of a CaMKII α promoter and (ii) a second heterologous nucleic acid sequence encoding a calcineurin inhibitor protein whose expression is under the control of a promoter responsive to the transcriptional activator in a regulatable manner, wherein the mammal exhibits enhanced calcineurin inhibitor protein expression on induction of the transcriptional activator.
2. (Original) The transgenic nonhuman mammal of claim 1, wherein the transcriptional activator comprises rtTA and the promoter of the second nucleic acid sequence comprises aa tetO-tetracycline-responsive sequence.
3. (Canceled).
4. (Currently Amended) The transgenic nonhuman mammal of claim 1 3, wherein the calcineurin inhibitor protein comprises the AI carboxy-terminal autoinhibitory sequence of calcineurin.
5. (Currently Amended) The transgenic nonhuman mammal of claim 1 3, wherein the expression of the calcineurin inhibitor protein is induced by doxycycline.
6. (Original) The transgenic nonhuman mammal of claim 1, wherein the transcriptional activator comprises tTA and the

promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.

7. (Canceled).

8. (Currently Amended) The transgenic nonhuman mammal of claim 7 6, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.

9. (Currently Amended) The transgenic nonhuman mammal of claim 7 6, wherein the expression of the calcineurin inhibitor protein is repressed by doxycycline.

10. (Original) The transgenic nonhuman mammal of claim 1, wherein the mammal is selected from the group consisting of a mouse, a rat, a sheep, a cow, a dog, a pig, and a primate.

11-20. (Canceled)

21. (Currently Amended) A nonhuman composition of matter comprising (i) a first nucleic acid encoding a transcriptional activator whose expression is under the control of a CaMKII α promoter and (ii) a second nucleic acid encoding a calcineurin inhibitor protein whose expression is under the control of a promoter responsive to the transcriptional activator in a regulatable manner, wherein the nonhuman composition of matter exhibits enhanced calcineurin inhibitor protein expression on induction of the transcriptional activator.

22. (Original) The composition of matter of claim 21, wherein the first and second nucleic acids exist in the same nucleic acid molecule.
23. (Original) The composition of matter of claim 21, wherein the transcriptional activator comprises rtTA and the promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.
24. (Canceled).
25. (Currently Amended) The composition of matter of claim ~~24~~ 21, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
26. (Currently Amended) The composition of matter of claim ~~24~~ 21, wherein the expression of the calcineurin inhibitor protein is induced by doxycycline.
27. (Original) The composition of matter of claim 21, wherein the transcriptional activator comprises tTA and the promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.
28. (Canceled).
29. (Currently Amended) The composition of matter of claim ~~28~~ 21, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
30. (Currently Amended) The composition of matter of claim ~~28~~ 21, wherein the expression of the calcineurin inhibitor protein is repressed by doxycycline.

Applicant: Isabelle Mansuy and Eric R. Kandel
U.S. Serial No.: 10/091,714
Filed: March 5, 2002
Page 5

31-34. (Canceled)